Self-assembled aggregation-induced emission nanoprobes for targeted therapy and real-time imaging of non-small cell lung cancer and application thereof

The self-assembled aggregation-induced emission nanoprobes (AIEnps) have enabled precise diagnosis and targeted therapy for non-small cell lung cancer, solving the problems of poor tumor penetration and drug resistance, and achieving the dual functions of real-time imaging and c-Met inhibition.

CN121362262BActive Publication Date: 2026-06-09THE AFFILIATED CENT HOSPITAL OF DALIAN UNIV OF TECH (DALIAN CENT HOSPITAL)
View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
THE AFFILIATED CENT HOSPITAL OF DALIAN UNIV OF TECH (DALIAN CENT HOSPITAL)
Filing Date
2025-10-30
Publication Date
2026-06-09

AI Technical Summary

Technical Problem

Existing technologies for the treatment of non-small cell lung cancer (NSCLC) suffer from poor tumor penetration, non-specific distribution, and drug resistance, making it difficult to achieve precise real-time tumor localization and effective targeted therapy.

Method used

We developed self-assembled aggregation-induced emission nanoprobes (AIEnps) that combine c-Met targeting sequences and microenvironment response design to achieve specific accumulation and fluorescence tracking of nanomaterials at tumor sites. By combining c-Met inhibitor functions, we can achieve targeted therapy and real-time imaging.

Benefits of technology

It effectively overcomes the problems of tumor penetration and non-specific distribution of traditional nanomedicines, enhances tumor targeting ability, realizes precise diagnosis and treatment of tumors and inhibits c-Met-mediated tumor growth, and reduces drug resistance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121362262B_ABST
    Figure CN121362262B_ABST
Patent Text Reader

Abstract

The application discloses a self-assembled aggregation-induced emission nanoprobes for targeted therapy and real-time imaging of non-small cell lung cancer and application, and belongs to the technical field of biological medicine. The self-assembled aggregation-induced emission nanoprobes AIEnps are used for targeting c-Met, and the AIEnps have a dual function: one is to realize real-time imaging through fluorescence tracing, and the other is to realize targeted therapy by inhibiting c-Met. The design based on AIE realizes tumor-specific accumulation and fluorescence tracing, overcomes the limitations of poor tumor permeability and non-specific distribution in traditional therapy, and the AIEnps are a multifunctional NSCLC treatment platform, integrating targeted therapy and real-time imaging, and have a very broad application prospect.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • AIE luminogens for visualization and treatment of cancer

    CN107849441A

  • AIE type fluorescent probe with tumor targeting property as well as preparation and application of AIE type fluorescent probe

    CN119552117A